CannPal Animal Therapeutics Limited announced that it has received 2 key ethics approvals to progress the research and development of the Company's lead therapeutic products, CPAT-01, a pain and inflammatory control being developed for dogs, and DermaCann, a nutraceutical product in development to promote canine skin health. CPAT-01 Osteoarthritis Study; The Phase 2A clinical study is a 6 to 8-week randomized, double-blind, placebo controlled, pilot dose determination study to explore the effects of various doses of CPAT-01 in client owned animals with osteoarthritis. Approximately 60 dogs will be enrolled in the study across various veterinary clinics in Australia, with recruitment to commence in first half of 2019 PAT-01 is the Company's lead pharmaceutical product in development for the control of pain and inflammation in dogs, a market estimated to be worth over USD 1 billion globally. CannPal is developing CPAT-01 as a regulatory approved cannabinoid derived veterinary medicine to be sold by veterinarians in major global markets. DermaCann Skin Study: The double blind placebo-controlled clinical trial for DermaCann is an 8 week efficacy study designed to explore the effects and confirm safety of the Company's lead nutraceutical product in dogs with skin conditions. Approximately 45 dogs will be enrolled for the study via specialist dermatology hospitals in NSW. DermaCann is CannPal's lead nutraceutical product being developed as a skin supplement for dogs which includes hemp derived CBD (cannabidiol). The global pet dietary supplement market for companion animals was worth over USD 1.3 billion in 2015, expected to reach over USD 1.8 billion BY 2021 with an estimated USD 440 million attributed to skin and coat supplements. Initially the Company intends to use the results from the upcoming study to prepare a dossier to seek complementary animal health product approval (CAHP) with the APVMA (Australian Pesticides and Veterinary Medicines Authority) to allow for the sale of DermaCann through Australian veterinarians.